|
|
||||||||
Division of Cardiothoracic Surgery and Cardiology, Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston, South Carolina 29425
| |
ABSTRACT |
|---|
|
|
|---|
Left ventricular (LV) pressure (PO) or volume (VO) overload is accompanied by myocardial remodeling, but mechanisms that contribute to this progressive remodeling process remain unclear. The matrix metalloproteinases (MMPs) contribute to tissue remodeling in a number of disease states. This study tested the hypothesis that increased MMP expression and activity occur after the induction of an LV overload, which is accompanied by a loss of endogenous MMP inhibitory control. LV MMP zymographic activity and species abundance were measured in dogs under the following conditions: acute PO induced by ascending aortic balloon inflation (6 h, n = 9), prolonged PO by aortic banding (10 days, n = 5), acute VO through mitral regurgitation secondary to chordal rupture (6 h, n = 6), prolonged VO due to mitral regurgitation (14 days, n = 7), and sham controls (n = 11). MMP zymographic activity in the 92-kDa region, indicative of MMP-9 activity, increased over threefold in acute PO and VO and fell to control levels in prolonged PO and VO. The MMP-9 activity-to-abundance ratio increased by over fourfold with acute VO and twofold in acute PO, suggesting a loss of inhibitory control. Endogenous MMP inhibitor content was unchanged with either PO or VO. Interstitial collagenase (MMP-1) content decreased by 50% with acute VO but not with acute PO. Stromelysin (MMP-3) levels increased by 40% with acute VO and increased by 80% with prolonged PO. Although changes in LV myocardial MMP activity and inhibitory control occurred in both acute and prolonged PO and VO states, these changes were not identical. These results suggest that the type of overload stimulus may selectively influence myocardial MMP activity and expression, which in turn would affect the overall LV myocardial remodeling process in LV overload.
myocardial remodeling; tissue inhibitor of metalloproteinases; hypertrophy; matrix metalloproteinase; left ventricular overload
| |
INTRODUCTION |
|---|
|
|
|---|
THE INDUCTION of a hemodynamic load to the left ventricle through either increased pressure (pressure overload, PO) or increased volume (volume overload, VO) results in significant myocardial remodeling (2, 6, 14, 17, 20, 24, 27, 29, 33, 41, 45). However, the pattern of myocardial remodeling is very different between PO and VO and has been hypothesized to be primarily due to differences in the left ventricular (LV) wall stress patterns, which result from these overload states (17). Specifically, PO due to aortic stenosis has been demonstrated to acutely increase LV systolic wall stress, which is normalized over time by increased LV wall thickness or concentric hypertrophy (2, 17, 24, 27). Whereas in VO such as that of mitral regurgitation, increased diastolic wall stress occurs and results in LV chamber enlargement or eccentric hypertrophy (24, 29). A fundamental event in the LV myocardial remodeling process with both forms of overload hypertrophy are changes in myocyte size and alignment within the LV free wall (6, 14, 20, 29, 41). The maintenance of myocyte shape, alignment, and overall architecture are critically dependent on the structural support provided by the extracellular collagen matrix (3, 10, 37, 45, 46). Past studies have demonstrated that alterations in the LV myocardial collagen interface, both in structure and composition, occur with both PO and VO states (29, 41, 45). The matrix metalloproteinases (MMPs) are an endogenous family of enzymes, which have been identified to be responsible for extracellular tissue remodeling in a number of physiological processes (8, 9, 19, 35, 43, 47). Increased activity of different species of MMPs can result in the degradation of a number of extracellular components, which include the collagens and basement membrane components such as laminin and fibronectin (8, 9, 19, 35, 43, 47). Thus changes in myocardial MMP activity may influence the stability of the LV myocyte-extracellular interface, which in turn would facilitate LV myocardial remodeling. Changes in LV myocardial MMP activity and expression have been identified to occur in end-stage human cardiomyopathic disease, as well as in several animal models of heart failure (18, 23, 40, 44). These past studies would suggest that myocardial MMP activation may contribute to the LV remodeling process. However, whether and to what degree changes in MMP expression and activity occur following either a PO or VO stimulus remained unexplored. Accordingly, the overall goal of the present study was to examine myocardial MMP activity and species expression following the induction of acute PO and VO, as well as following a more prolonged period of both LV overload conditions.
The classification of MMPs was originally developed to reflect substrate specificity, but several MMPs exhibit activity against a wide range of matrix proteins. Whereas a large number of MMPs have been identified in various tissues and cell systems, there are specific classes of MMPs that likely have particular relevance to myocardial remodeling (8, 18, 23, 40, 44). These include the gelatinases such as MMP-9 and MMP-2, interstitial collagenases such as MMP-1, and the stromelysins such as MMP-3. Accordingly, the present study examined the relative myocardial abundance of these MMP species following PO or VO. An important control point of MMP activity is inhibition of the active MMP enzyme. Inhibition of active MMP enzyme can occur through an endogenous class of proteins called the tissue inhibitors of the MMPs, or TIMPs (5, 15, 31). Thus increased myocardial MMP activity may be due to increased abundance of MMPs or alterations in inhibitory control by TIMPs. To address this issue, the present study quantified the myocardial expression of TIMP-1, a TIMP that has been identified to play an important regulatory role in MMP activity (5, 15, 31). The process by which TIMPs modulate MMP activity is through direct binding to the catalytic site of the activated MMP by forming a tight covalent complex (5, 31). Thus control of MMP activity in vivo is not only dependent on the total amount of TIMP available but the degree of actual MMP-TIMP complexes that are formed. Accordingly, the present study directly measured myocardial MMP/TIMP complex formation following the induction of PO or VO. The guiding hypothesis for the experiments performed was that increased MMP activity and expression occur early following the induction of an LV overload stimulus, which is coupled by a loss of MMP inhibitory control.
| |
METHODS |
|---|
|
|
|---|
Induction of acute and prolonged PO and VO.
This study measured MMP activity, expression, and TIMP profiles after
the acute and prolonged PO induced by aortic stenosis in dogs as
described previously (24). For the VO studies, measurements were
performed after the creation of VO due to mitral regurgitation in dogs
(6, 29, 41). The effects on systemic hemodynamics and indexes of LV
ejection performance in these overload states have been well
characterized previously (2, 6, 24, 29, 41). For the present series of
studies, adult mongrel dogs (21-23 kg) were anesthetized with 0.15 ml/kg of fentanyl-droperidol (Innovar Vet, Pitmen-Moore, Washington
Crossing, NJ), intubated, and ventilated with nitrous oxide and oxygen
(1:3 ratio). Anesthesia was maintained throughout the studies by
sufentanyl (0.15 mg · kg
1 · min
1)
and 1% isoflurane. The right and left femoral vessels were exposed through a sterile incision, and a multilumen thermodilution catheter (7.5 Fr; Baxter Healthcare, Irvine, CA) was positioned in the pulmonary
artery via the left femoral vein. With this catheter, thermodilution-derived cardiac output and pulmonary capillary wedge
pressure were measured. For the acute PO studies, an 18-mm balloon
catheter was advanced from the femoral artery and positioned in the
aortic arch by fluoroscopic guidance, and the balloon was inflated to
achieve an LV systolic pressure of approximately 180 mmHg. The LV
systolic pressure was kept between 170 and 190 mmHg to maintain a mean
femoral artery pressure of 50 mmHg for 6 h (n = 9) (22). A constant
heart rate was maintained during balloon inflation by atrial pacing at
100 beats/min. Prolonged PO was produced through direct aortic banding
using an external balloon dilation catheter, which was placed by a left
thoracotomy (22, 24). After recovery from the procedure, the balloon
was inflated to produce a 75% increase in LV systolic pressure, which
was maintained for 10 days (n = 5).
Acute VO was produced by chordal rupture with urological stone grasping
forceps as described previously (6, 29, 41). Adequate VO due to mitral
regurgitation was defined as a pulmonary capillary wedge pressure of 20 mmHg and over a 50% reduction in thermodilution stroke volume (6, 29, 41). Severe mitral regurgitation was also visually confirmed angiographically in each case. Acute VO was defined as 6 h following the induction of mitral regurgitation
(n = 6), and prolonged VO was defined
as 14 days following the induction of the mitral regurgitation (n = 7). A separate group of
sham-operated controls were used for comparison purposes
(n = 11). At the end of the PO or VO
protocols, LV pressures and volumes were obtained and wall-stress
computations were performed as well described previously (6, 24, 29, 41). Briefly, through the carotid artery, a 5-Fr pigtail catheter was
advanced into the LV for contrast dye injection and a micromanometer catheter (7.5 Fr; Millar Instruments, Houston, TX) was advanced through
the same artery into the LV. Nonionic contrast material was injected into the LV, and the opacified image was filmed at 60 frames/s in the 30° right anterior oblique position (Cardio Diagnostics; Philips Medical Systems, Sherton, CT) while simultaneously recording LV pressure. LV end-diastolic and end-systolic volumes and
wall thickness were computed from the ventriculograms, and with the
temporally aligned LV pressures, peak-systolic and end-diastolic circumferential wall stress was computed (2, 6, 17, 24, 29, 41). After
this procedure the animals were euthanized by anesthetic overdose, and
the LV was quickly harvested, weighed, and placed in a
phosphate-buffered ice slush. Full thickness sections of the LV
myocardium were then placed in liquid nitrogen and stored at
70°C until the time of assay. All animals were treated and cared for in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory
Animals, National Research Council, Washington, DC, 1996.
LV zymographic MMP activity. The LV myocardial samples were prepared for zymographic studies as described previously (40, 44). Briefly, the samples were homogenized in an ice-cold extraction buffer solution maintaining a low pH to prevent proteolytic activation during the extraction process. The homogenate was then centrifuged (4°C, 10 min, 1,200 g), the supernatant concentrated (Centriplus; Millipore, Bedford, MA), and the final protein concentration of the myocardial extracts was determined (Bio-Rad Protein Assay; Bio-Rad, Richmond, CA). Relative LV MMP gelatinase activity was examined by substrate-specific zymographic analysis as described previously (18, 23, 40, 44). The LV myocardial extracts (6 µg total protein) were loaded onto electrophoretic gels (SDS-PAGE) containing 1 mg/ml of gelatin. After SDS-PAGE, the gels were washed and incubated for 12 h in an MMP substrate buffer at 37°C. After incubation, the gels were stained using 0.1% amido black and destained in water. To provide an internal control with respect to the zymographic activity, samples were collected from the conditioned cell culture media of a human fibrosarcoma HT-1080 cell line (40, 44). The zymograms were digitized and the size-fractionated banding pattern, which indicated MMP proteolytic activity, was determined by quantitated image analysis (Gel Pro Analyzer; Media Cybernetics, Silver Spring, MD). The lysis areas were measured by two-dimensional integrated optical density, and computations were expressed in pixels.
LV myocardial MMP, TIMP, and MMP/TIMP complex measurements. An ELISA was used for quantitation of specific species of MMPs in the LV myocardial samples. With a two-site ELISA sandwich format and internal standards, quantitative analysis for MMP-1, MMP-2, MMP-9, TIMP-1, as well as the MMP-1/TIMP-1 complex, was performed (RPN 2610-2614, BIOTRAK; Amersham Life Sciences, Buckinghamshire, UK) using previously described techniques (32, 49). For this procedure, the MMP, TIMP-1, or MMP-1/TIMP-1 antibody was coated to the bottom of microtiter wells (mouse anti-human). MMP or TIMP standards and LV myocardial samples (100 µg total protein) were then incubated at 25°C for 2 h. The standards and samples were then aspirated, the plates were washed with 0.1 M phosphate buffer (pH 7.5), and the wells were filled with a polyclonal rabbit antibody and incubated for 2 h. The wells were then washed, and a conjugated donkey anti-rabbit antibody was placed in each well and incubated for 1 h. After another series of washes, the reaction was initiated by the addition of 3,3',5,5'-tetramethylbenzidine-hydrogen peroxide in dimethylformamide (30% vol/vol). The reaction was allowed to proceed for 30 min and then terminated by the addition of 100 µl of 1 M sulfuric acid, and the plate was read at 450 nm (Vmax Kinetic Microplate Reader; Molecular Devices). This ELISA method was highly linear with increasing concentrations of MMP, TIMP, and MMP-TIMP complex standards. With these standards a regression curve was generated, and results were expressed as nanograms per gram of LV myocardium. All assays were performed in triplicate, and the intra-assay variability was less than 15%.
Immunoblotting for MMP-3. An internally validated ELISA method was not available for MMP-3, and therefore immunoblotting was performed using previously described methods and a well-characterized antibody (40, 44). LV extracts (10 µg total protein) were loaded on an 8% SDS-polyacrylamide gel and separated at 40 mA in 0.02 M Tris base, 0.2 M glycine, pH 6.8, containing 0.1% SDS. The separated proteins were transferred to a polyvinylidene fluoride membrane (0.45 µm; Millipore, Bedford, MA) in 0.025 M Tris base, 0.2 M glycine, pH 8.2, containing 20% methanol (vol/vol). Membranes were blocked with 0.2 M Tris base, 1.4 M NaCl, pH 7.6, containing 10% nonfat dry milk, 0.01% Tween 20, and 0.02% NaN3. After a wash with 0.2 M Tris base, 1.4 M NaCl, pH 7.6, containing 0.1% Tween 20, membranes were incubated overnight at 4°C in a monoclonal antibody solution (1.0 µg/ml, IM36L Oncogene Research Products, Cambridge, MA). After stringent washing, the membranes were incubated for 1 h in a horseradish peroxidase-conjugated goat anti-mouse antibody (1:5,000 dilution, Bio-Rad Laboratories, Hercules, CA). The membranes were washed again, and the horseradish peroxidase-conjugated secondary antibody was activated with peracid and luminol (ECL-Plus; Amersham Life Science, Arlington Heights, IL). The luminescent signal was detected by exposure to X-ray film (Eastman Kodak, Rochester, NY). A positive control was included in all immunoblots (AG770; Chemicon International, Tenecada, CA). Prestained molecular weight markers (Bio-Rad Laboratories) were used to ensure adequate protein separation and transfer. The intensity of the signal was quantitated using densitometric methods and normalized to control values.
Data analysis. For comparisons of hemodynamics with each treatment, an ANOVA was first performed and if the ANOVA revealed significant differences, pair-wise tests of individual group means were compared using Bonferroni probabilities. The comparisons of MMP zymographic activity and abundance by ELISA were performed in a similar fashion. For the relative comparisons between groups for the MMP-3 immunoblotting results, the Kruskal-Wallis ANOVA was employed. A relationship was determined between the quantitative ELISA and zymographic data and the end-systolic and end-diastolic wall stress values using regression analysis. Linear regression was first performed in which the independent variable was LV wall stress. Multiple linear regression modeling was then performed in which the independent variables were LV wall stress and the treatment intervention (none, PO, or VO). All statistical procedures were performed using the BMDP statistical software package (BMDP Statistical Software, Los Angeles, CA). Results are presented as means ± SE.
| |
RESULTS |
|---|
|
|
|---|
The LV-aorta pressure gradient during the 6 h of acute PO due to aortic stenosis was 126 ± 4 mmHg, and after 10 days of prolonged PO it was 84 ± 18 mmHg. After 6 h of acute VO due to mitral regurgitation the regurgitant fraction was 70 ± 3%, and after 14 days of VO it was 63 ± 5%. LV mass increased in prolonged PO compared with control values (6.3 ± 0.2 vs. 4.3 ± 0.3 g/kg, respectively, P < 0.05). LV mass was increased from control values after prolonged VO (5.1 ± 0.4 g/kg), but this did not reach statistical significance (P = 0.08). The LV mass-to-end-diastolic volume ratio decreased with acute PO compared with control values (0.76 ± 0.02 vs. 1.26 ± 0.12 g/ml, respectively, P < 0.05). With prolonged PO, LV mass/end-diastolic volume increased from control values (2.06 ± 0.17 g/ml, P < 0.05). With acute VO, there was a small but significant fall in this value from control (1.19 ± 0.02 g/ml, P = 0.047). The LV mass-to-end-diastolic volume ratio returned to control values with prolonged mitral regurgitation (1.21 ± 0.11 g/ml). Thus, as reported previously, these two forms of LV overload resulted in a different hypertrophic response and subsequently different patterns of LV wall stress (6, 24, 29, 41).
LV myocardial MMP zymographic activity.
Total MMP zymographic activity was computed by densitometric analysis
of all gelatinolytic zones from 60 to 100 kDa, which likely reflect
several species of MMPs (9, 19, 43, 47). Total MMP zymographic activity
did not increase from control values with acute PO (1,365 ± 142 vs.
1,237 ± 118 pixels, respectively) or with prolonged PO (1,027 ± 96 pixels). However, as shown in Fig. 1, an
emergence of a strong 92-kDa lytic zone was observed with acute PO,
which corresponds to the substrate specificity and molecular weight of
MMP-9 (43, 47). With acute and prolonged VO, total zymographic activity
was unchanged from controls (1,190 ± 142 vs. 1,247 ± 316 pixels, respectively). However, as with acute PO, acute VO resulted
in a significant increase in 92-kDa gelatinolytic activity (Fig.
2). Thus, after the acute induction of
either PO or VO, increased MMP-9 zymographic activity occurred.
|
|
LV myocardial MMP abundance.
LV myocardial content for different species of MMPs, TIMP-1, and the
MMP/TIMP-1 complex following acute and prolonged PO and VO is
summarized in Table 1. With prolonged PO,
MMP-1 abundance was reduced from control values. After both acute and
prolonged VO, MMP-1 levels were reduced from controls. MMP-2 levels
were unchanged with acute PO and were reduced with prolonged PO. MMP-2 levels remained unchanged with either acute or prolonged VO. MMP-9 levels remained unchanged with either acute or prolonged PO and tended
to decrease with acute and prolonged VO, but this did not reach
statistical significance (P = 0.09 and
0.10, respectively). Overall, TIMP-1 levels were unchanged with either
acute or prolonged PO or VO. The abundance of MMP-1/TIMP-1 myocardial
complexes was unchanged with acute PO or VO. MMP-1/TIMP-1 levels were
significantly reduced with prolonged PO and tended to decrease with
prolonged VO (P = 0.16). Thus
differential responses were elicited with respect to MMP-1, MMP-2, and
MMP-1/TIMP-1 abundance between PO and VO states.
|
|
|
|
LV wall stress patterns and MMP expression.
The potential relationship between changes in LV wall stress patterns,
which were induced with either PO or VO, were examined with respect to
quantifiable indexes of MMP activity and inhibitory control. With MMP-9
zymographic activity as the dependent variable, there was a positive
relationship with LV peak-systolic wall stress after the induction of
acute PO (Fig. 6). With VO, LV
end-diastolic wall stress was significantly associated with MMP-9
zymographic activity (Fig. 6). LV peak-systolic wall stress was
strongly associated with a change in TIMP-1 levels in PO, whereas
increased diastolic stress was associated with decreased TIMP-1 values
in VO (Fig. 7). There was an apparent
association between LV myocardial levels of the MMP-1/TIMP-1 complex
and changes in LV wall stress patterns with PO and VO; however, there
was a significant degree of variability associated with this parameter
(Fig. 8). Overall, LV myocardial MMP-1/TIMP-1 complex levels were positively associated with LV peak-systolic stress in PO and negatively correlated in VO.
|
|
|
0.30,
P = 0.18) or end-diastolic
(r =
0.18,
P = 0.42) wall stress. For TIMP-1 levels, linear regression modeling revealed that the type of overload was a significant independent variable when considered with
peak-systolic stress (r =
0.63,
P < 0.01). The type of overload
stimulus was not identified as an independent variable when considered
with LV end-diastolic wall stress in a multiple linear regression model with TIMP-1 as the dependent variable
(r =
0.33,
P = 0.17). The type of overload state
was not an independent variable for MMP-1/TIMP-1 levels for either peak
systolic (r = 0.01, P = 0.96) or end-diastolic (r =
0.26,
P = 0.31) wall stress.
| |
DISCUSSION |
|---|
|
|
|---|
The myocardial collagen scaffold has been postulated to play an important role in maintaining the alignment of myofibrils within the myocyte through a collagen-cytoskeletal-myofibril interface, which may also be important for the transduction of extracellular mechanical signals (3, 10, 37, 45, 46). Thus alterations in the normal three-dimensional extracellular network due to enzymatic cleavage by the MMPs may facilitate changes in LV function and geometry. Several recent clinical and basic studies have demonstrated increased LV myocardial MMP activity with end-stage LV failure (18, 23, 26, 31, 40, 44). However, there have been no studies to date that have systematically examined LV myocardial MMP activity and species expression following the imposition of either a PO or VO. The present study measured MMP activity, species abundance, and indexes of MMP activational control in dogs following acute and prolonged PO or VO. Acute PO and VO resulted in increased MMP zymographic activity consistent with increased activation of MMP-9. This increased MMP activity was not paralleled by increased MMP-9 or TIMP-1 protein levels, suggestive of diminished inhibitory control. With acute VO but not acute PO, MMP-1 levels were reduced most probably due to increased activation and clearance of endogenous MMP-1 stores. In contrast, MMP-2 and MMP-1/TIMP-1 complex formation was reduced with prolonged PO but not VO. Finally, MMP-3 levels were increased with acute VO, whereas the levels for this MMP species were increased only with prolonged PO. The alterations in MMP activity and species abundance occurred following the induction of either PO or VO, but these changes were not identical in both forms of LV overload. Thus MMP activation and expression may be dependent on the pattern of mechanical load imposed on the myocardium. These unique results provide evidence that several species of MMPs exist within the myocardium that are modified following the induction of a PO or VO stimulus, which in turn may contribute to the LV myocardial remodeling process in these two forms of hypertrophy.
Myocardial MMP abundance with PO or VO.
In the present study, acute VO but not acute PO, was associated with a
significant reduction in the myocardial content of MMP-1 and increased
MMP-3. With prolonged PO, a reduction in MMP-1 and MMP-2 and increased
MMP-3 was observed. Thus some difference in the temporal profile of MMP
species abundance was observed between these two LV overload
conditions. These results suggest that different chemical and
mechanical signals are produced with PO and VO, which in turn would
influence MMP expression. Although a diverse repertoire
of signals can influence changes in MMP expression, one important
intracellular event appears to be linked to the AP-1 binding site which
also forms the phorbol-ester-responsive element on certain MMP genes
(12, 35, 38, 39). It is likely that protein kinase C (PKC) is involved
in the intracellular induction of MMP transcription because the
exposure of several different cell systems to phorbol esters, which
increase PKC levels and activation, causes increased MMP mRNA
expression (12, 35, 38, 39). Bioactive molecules such as
catecholamines, angiotensin II, and endothelin, through specific
receptor activation, can modulate intracellular PKC levels. There are
several past reports that have demonstrated that the local production
of angiotensin II and endothelin occur with PO- or VO-induced
hypertrophy (6, 7, 11, 13). Local activation of these receptor
transduction pathways following the induction of PO or VO would likely
influence MMP expression via a PKC-dependent mechanism. The
MMP-1 and
MMP-3 genes contain elements in the
promoter region, which bind protooncogene products of the
fos and
jun family (12, 39).
However, the present study did not measure circulating or tissue levels
of bioactive peptides or cytokines, which may have directly contributed to the changes in MMP levels that were observed. Bioactive peptides and
cytokines, such as tumor necrosis factor-
and interleukin-1, which
stimulate the production of protooncogenes, have been demonstrated to
increase MMP transcription in several cell systems (4, 28, 36).
However, it is also possible that the imposition of an LV overload
caused alterations in MMP mRNA stability or protein synthesis rates.
Based on the results obtained in the present study, future studies that
more carefully determine the basis for the changes in MMP myocardial
levels in LV overload states would be warranted.
Myocardial MMP activity with PO or VO. Because MMPs are primarily secreted in an inactive or pro-MMP form, MMP activation occurs following secretion into the extracellular space (8, 9, 19, 21, 31, 42, 43, 47). Thus an important control point for MMP activity is proteolytic processing of the pro-MMPs. One of the most frequently studied MMPs with respect to zymogen activation is the interstitial collagenase MMP-1 (19, 21, 30, 42, 43, 47). The first step in MMP-1 activation is proteolytic cleavage ahead of the cysteine residue, which results in a partially active intermediate form that is then quickly converted to the active form by autolytic means or through cleavage by MMP-3 (21, 30, 42). Thus an important regulatory step in overall MMP activation involves the expression and activational state of MMP-3. Increased myocardial levels and activity of MMP-3 have been reported to occur in both humans and animals with LV dilation and failure (40, 44). In the present study, MMP-3 was increased with acute VO and therefore provided an increased capacity for MMP-1 proteolytic activation. The reduced MMP-1 levels which occurred concomitantly with increased MMP-3 levels following the induction of acute VO would support this hypothesis.
In the present study increased 92-kDa zymographic activity occurred with both acute PO and VO, which is consistent with the activity and substrate specificity of the 92-kDa gelatinase MMP-9 (8, 9, 19). The increased MMP-9 zymographic activity with PO and VO was not associated with changes in absolute enzyme abundance. These findings would suggest that the increased MMP-9 activity observed with acute PO and VO was due to an increased activational state. As discussed in the following section, this is probably due to a loss in MMP inhibitory control. However, it must be recognized that the in vitro zymographic technique requires electrophoretic separation of the MMP proteins and therefore only provides an index of potential MMP activational states which may exist in vivo.TIMPs with PO or VO. The TIMPs are low-molecular-weight proteins that can complex with high efficiency to activated MMPs. Therefore, TIMPs form an important endogenous system for regulating actual MMP activity in vivo. The first well-characterized TIMP was TIMP-1, which binds to a number of activated MMPs (5, 15). In the present study, TIMP-1 levels were unchanged with either PO or VO. However, the ratio of MMP-9 activity to MMP-9 abundance and the ratio of MMP-9 activity to TIMP-1 levels were both significantly increased, particularly with acute VO. These results would suggest a loss of inhibitory control of MMP activity. Furthermore, the abundance of MMP-1/TIMP-1 complexes within the myocardium were reduced in prolonged PO, which would also suggest that alterations in MMP-TIMP stoichiometry occurred in this overload state. Several past studies have provided evidence to suggest that changes in the stoichiometric ratio of MMPs to TIMPs have occurred with end-stage cardiomyopathic disease (26, 44). At present, there are four TIMPs that have been characterized with respect to being separate gene products which influence the activity of MMPs (5, 8, 9, 15, 16, 19, 25). More recently a high expression pattern for TIMP-4 was reported in the myocardium (16). However, whether TIMP-4 possesses different MMP inhibitory activity within the myocardium remains to be established. In light of the findings from the present study, future investigations focused on the function and regulation of these various TIMP species in LV overload states would be warranted.
| |
ACKNOWLEDGEMENTS |
|---|
We acknowledge the technical assistance of Gilberto Defreyte.
| |
FOOTNOTES |
|---|
The work was supported by the National Heart, Lung, and Blood Institute Grants HL-45024 (F. G. Spinale), HL-97012 (F. G. Spinale), PO1-HL-48788 (P. J. McDermott, B. A. Carabello, F. G. Spinale); Research Service of the Department of Veterans Affairs (B. A. Carabello); and American Heart Association Grant-in-Aid (F. G. Spinale). F. G. Spinale is an Established Investigator of the American Heart Association.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: F. G. Spinale, Cardiothoracic Surgery, Rm. 625, Strom Thurmond Research Bldg., 770 MUSC Complex, Medical Univ. of South Carolina, 114 Doughty St., Charleston, SC 29425.
Received 17 December 1998; accepted in final form 3 August 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Aggeler, J.,
S. M. Frisch,
and
Z. Werb.
Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts.
J. Cell Biol.
98:
1662-1671,
1984
2.
Aoyagi, T.,
A. M. Fujii,
M. F. Flanagan,
L. W. Arnold,
K. W. Brathwaite,
S. D. Colan,
and
I. Mirsky.
Transition from compensated hypertrophy to intrinsic myocardial dysfunction during development of left ventricular pressure-overload hypertrophy in conscious sheep: systolic dysfunction precedes diastolic dysfunction.
Circulation
88:
2415-2425,
1993
3.
Borg, T. K.,
and
L. Terracio.
Interaction of the extracellular matrix with cardiac myocytes during development and disease.
In: Cardiac Myocyte-Connective Tissue Interactions in Health and Disease, edited by T. R. Robinson,
and R. K. H. Kinne. Basel: Karger, 1990, p. 113-130.
4.
Brenner, D. A.,
M. O'Hara,
P. Angel,
M. Chojkler,
and
M. Karin.
Prolonged activation of jun and collagenase genes by tumor necrosis factor-alpha.
Nature
337:
661-663,
1989[Medline].
5.
Cawston, T. E.,
V. A. Curry,
I. M. Clark,
and
B. L. Hazleman.
Identification of a new metalloproteinase inhibitor that forms tight-binding complexes with collagenase.
Biochem. J.
269:
183-187,
1990[ISI][Medline].
6.
Dell'Italia, L. J.,
E. Balcells,
Q. C. Meng,
X. Su,
D. Schultz,
S. P. Bishop,
N. Machida,
I. M. Straeter-Knowlen,
G. H. Hankes,
R. Dillon,
R. E. Cartee,
and
S. Oparil.
Volume overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs.
Am. J. Physiol. Heart Circ. Physiol.
273:
H961-H970,
1997
7.
Dell'Italia, L. J.,
Q. C. Meng,
E. Balcells,
I. M. Straeter-Knowlen,
G. Hankes,
R. Dillon,
R. E. Carter,
R. Orr,
S. P. Bishop,
S. Oparil,
and
T. S. Elton.
Increased ACE and chymase-like activity in cardiac tissue of dogs with chronic mitral regurgitation.
Am. J. Physiol. Heart Circ. Physiol.
269:
H2065-H2073,
1995
8.
Dollery, C. M.,
J. R. McEwan,
and
A. M. Henney.
Matrix metalloproteinases and cardiovascular disease.
Circ. Res.
77:
863-868,
1995
9.
Edwards, D. R.,
P. P. Beaudry,
T. D. Laing,
V. Kowal,
K. J. Leco,
P. A. Leco,
and
M. S. Lim.
The roles of tissue inhibitors of metalloproteinases in tissue remodeling and cell growth.
Int. J. Obes.
20, Suppl.:
S9-S15,
1996.
10.
Factor, S. M.
Role of extracellular matrix in dilated cardiomyopathy.
Heart Failure
8:
260-268,
1994.
11.
Fareh, J.,
R. M. Touyz,
E. L. Schiffrin,
and
G. Thibault.
Endothelin-1 and angiotensin II receptors in cells from rat hypertrophied heart. Receptor regulation and intracellular Ca2+ modulation.
Circ. Res.
78:
302-311,
1996
12.
Frisch, S. M.,
and
J. H. Morisaki.
Positive and negative transcriptional elements of the human type IV collagenase gene.
Mol. Cell. Biol.
10:
6524-6532,
1990
13.
Gavras, H.
Angiotensin converting enzyme inhibition and the heart.
Hypertension
23:
813-818,
1994
14.
Gerdes, A. M.,
S. E. Campbell,
and
D. R. Hilbelink.
Structural remodeling of cardiac myocytes in rats with arteriovenous fistulas.
Lab. Invest.
59:
857-861,
1988[ISI][Medline].
15.
Goldberg, G. I.,
B. L. Marmer,
G. A. Grant,
A. Z. Eisen,
S. Wilhelm,
and
C. He.
Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloprotease designated TIMP.
Proc. Natl. Acad. Sci. USA
86:
8207-8211,
1989
16.
Green, J.,
M. Wang,
Y. E. Liu,
L. A. Raymond,
C. Rosen,
and
Y. E. Shi.
Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4.
J. Biol. Chem.
271:
30375-30380,
1996
17.
Grossman, W.,
D. Jones,
and
L. P. McLaurin.
Wall stress patterns of hypertrophy in the human left ventricle.
J. Clin. Invest.
56:
56-64,
1975.
18.
Gunja-Smith, Z.,
A. R. Morales,
R. Romanelli,
and
J. F. Woessner.
Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy: role of metalloproteinases and pyridinoline cross links.
Am. J. Pathol.
148:
1639-1648,
1996[Abstract].
19.
Hansen-Birkedal, H.,
W. G. I. Moore,
M. K. Bodden,
L. J. Windsor,
B. Hansen-Birkedal,
A. DeCarlo,
and
J. A. Engler.
Matrix metalloproteinases: a review.
Crit. Rev. Oral Biol. Med.
4:
197-250,
1993
20.
Hatt, P. Y.,
K. Rakusan,
P. Gastineau,
and
M. Laplace.
Morphometry, and ultrastructure of heart hypertrophy induced by chronic volume overload (aorto-caval fistula in the rat).
J. Mol. Cell. Cardiol.
11:
989-998,
1979[ISI][Medline].
21.
He, C.,
S. M. Wilhelm,
A. P. Pentland,
B. L. Marmer,
G. A. Grant,
A. Z. Eisen,
and
G. I. Goldberg.
Tissue cooperation in a proteolytic cascade activating human interstitial collagenase.
Proc. Natl. Acad. Sci. USA
86:
2632-2636,
1989
22.
Imamura, T.,
P. J. McDermott,
R. L. Kent,
M. Nagatsu,
G. Cooper IV,
and
B. A. Carabello.
Acute changes in myosin heavy chain synthesis rate in pressure versus volume overload.
Circ. Res.
75:
418-425,
1994
23.
Janicki, J. S.,
J. R. Henegar,
S. E. Campbell,
and
S. C. Tyagi.
Myocardial collagenase activity in experimental dilated cardiomyopathy.
In: Wound Healing in Cardiovascular Disease, edited by K. T. Weber. New York: Futura, 1995, p. 73-81.
24.
Koide, M.,
M. Nagatsu,
M. R. Zile,
M. Hamawaki,
M. M. Swindle,
G. Keech,
G. DeFreyte,
H. Tagawa,
G. Cooper,
and
B. A. Carabello.
Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine.
Circulation
95:
1601-1610,
1997
25.
Leco, K. J.,
R. Khokha,
N. Pavloff,
S. P. Hawkes,
and
D. R. Edwards.
Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix associated protein with a distinctive pattern of expression in mouse cells and tissues.
J. Biol. Chem.
269:
9352-9360,
1994
26.
Li, Y. Y.,
A. M. Feldman,
Y. Sun,
and
C. F. McTiernan.
Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.
Circulation
98:
1728-1734,
1998
27.
Linzbach, A. J.
Heart failure from the point of view of quantitative anatomy.
Am. J. Cardiol.
5:
370-382,
1960[ISI][Medline].
28.
MacNaul, K. L.,
N. Chartrain,
M. Lark,
M. J. Tocci,
and
N. I. Hutchinson.
Discordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts: synergistic effects of interleukin-1 and tumor necrosis factor-
on stromelysin expression.
J. Biol. Chem.
265:
17238-17245,
1990
29.
Matsuo, T.,
B. A. Carabello,
Y. Nagatomo,
M. Koide,
M. Hamawaki,
M. R. Zile,
and
P. J. McDermott.
Mechanisms of cardiac hypertrophy in canine volume overload.
Am. J. Physiol. Heart Circ. Physiol.
275:
H65-H74,
1998
30.
Murphy, G.,
M. I. Cockett,
P. E. Stephens,
B. J. Smith,
and
A. J. Docherty.
Stromelysin is an activator of procollagenase.
Biochem. J.
248:
265-268,
1987[ISI][Medline].
31.
Nagase, H.
Activational mechanisms of matrix metalloproteinases.
Biol. Chem.
378:
151-160,
1997.
32.
Obata, K.,
K. Iwata,
Y. Okada,
Y. Kohrin,
E. Ohuchi,
S. Yoshida,
M. Shinmei,
and
T. Hayakawa.
A one step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies.
Clin. Chim. Acta
211:
59-72,
1992[ISI][Medline].
33.
Olivetti, G.,
R. Ricci,
C. Lagrasta,
E. Maniga,
E. H. Sonnenblick,
and
P. Anversa.
Cellullar basis of wall remodeling in long-term pressure overload-induced right ventricular hypertrophy in rats.
Circ. Res.
63:
648-657,
1988
34.
Overall, C. M.,
J. L. Wrana,
and
J. Sodek.
Transcriptional and post-transcriptional regulation of 72 kDa gelatinase/type IV collagenase by transforming growth factor
-1 in human fibroblasts.
J. Biol. Chem.
266:
14064-14071,
1991
35.
Rees, R. C.,
and
D. W. Cottam.
Regulation of the matrix metalloproteinases: their role in tumor invasion and metastasis (review).
Int. J. Oncol.
2:
861-872,
1993[ISI].
36.
Ries, C.,
and
P. E. Petrides.
Cytokine regulation of matrix metalloproteinase activity and regulatory dysfunction in disease.
Biol. Chem.
376:
345-355,
1995.
37.
Robinson, T. F.,
L. Cohen-Gould,
and
S. M. Factor.
Skeletal framework of mammalian heart muscle. Arrangement of inter- and pericellular connective tissue structures.
Lab. Invest.
49:
482-498,
1983[ISI][Medline].
38.
Saito, H.,
and
M. Seiki.
Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells.
Oncogene
8:
395-405,
1993[ISI][Medline].
39.
Shonthal, A.,
P. Herrlich,
H. J. Rahmsdorf,
and
H. Ponta.
Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters.
Cell
54:
325-334,
1988[ISI][Medline].
40.
Spinale, F. G.,
M. L. Coker,
C. V. Thomas,
J. D. Walker,
R. Mukherjee,
and
L. Hebbar.
Time dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function.
Circ. Res.
82:
482-495,
1998
41.
Spinale, F. G.,
K. Ishihra,
M. Zile,
G. DeFryte,
F. A. Crawford,
and
B. A. Carabello.
The structural basis for changes in left ventricular function, and geometry due to chronic mitral regurgitation and following correction of the volume overload.
J. Thorac. Cardiovasc. Surg.
106:
1147-1157,
1993[Abstract].
42.
Springman, E. B.,
E. L. Angelton,
H. Birkedal-Hansen,
and
H. E. van Wart.
Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of the Cys73 active site zine complex in latency and a "cysteine switch" mechanism for activation.
Proc. Natl. Acad. Sci. USA
87:
364-368,
1990
43.
Stetler-Stevenson, W. G.
Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix.
Am. J. Pathol.
148:
1345-1350,
1996[ISI][Medline].
44.
Thomas, C. V.,
M. L. Coker,
J. L. Zellner,
J. R. Handy,
A. J. Crumbley,
and
F. G. Spinale.
Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.
Circulation
97:
1708-1718,
1998
45.
Weber, K. T.,
P. Anversa,
P. W. Armstrong,
C. G. Brilla,
J. C. Burnett,
J. M. Cruickshank,
R. B. Devereux,
T. D. Giles,
N. Korsgaard,
C. V. Leier,
F. A. O. Mendelsohn,
W. H. Motz,
M. J. Mulvany,
and
B. E. Strauer.
Remodeling and reparation of the cardiovascular system.
J. Am. Coll. Cardiol.
20:
3-16,
1992[Abstract].
46.
Weber, K. T.,
and
C. G. Brilla.
Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin system.
Circulation
83:
1849-1865,
1991
47.
Werb, Z.,
and
C. M. Alexander.
Proteinases and matrix degradation.
In: Textbook of Rheumatology, edited by W. N. Kelly,
E. D. Harris,
S. Ruddy,
and C. B. Sledge. Philadelphia, PA: Saunders, 1993, p. 248-268.
48.
Werb, Z.,
R. M. Hembry,
G. Murphy,
and
J. Aggeler.
Commitment to expression of the metalloendopeptidases, collagenase and stromelysin: relationship of inducing events to changes in cytoskeletal architecture.
J. Cell Biol.
102:
697-702,
1986
49.
Zhang, J.,
N. Fujimoto,
K. Iwata,
T. Sakai,
Y. Okada,
and
T. Hayakawa.
A one step sandwich enzyme immunoassay for human matrix metalloproteinase 1 (interstitial collagenase) using monoclonal antibodies.
Clin. Chim. Acta
219:
1-14,
1993[ISI][Medline].
This article has been cited by other articles:
![]() |
F. G. Spinale Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function Physiol Rev, October 1, 2007; 87(4): 1285 - 1342. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, G. Zhang, L. Benson, H. Holtby, S. Cai, T. Humpl, G. S. Van Arsdell, A. N. Redington, and C. A. Caldarone Comparison of the Profiles of Postoperative Systemic Hemodynamics and Oxygen Transport in Neonates After the Hybrid or the Norwood Procedure: A Pilot Study Circulation, September 11, 2007; 116(11_suppl): I-179 - I-187. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Morita, S. Khanal, S. Rastogi, G. Suzuki, M. Imai, A. Todor, V. G. Sharov, S. Goldstein, T. P. O'Neill, and H. N. Sabbah Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2522 - H2527. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Matsusaka, T. Ide, S. Matsushima, M. Ikeuchi, T. Kubota, K. Sunagawa, S. Kinugawa, and H. Tsutsui Targeted Deletion of Matrix Metalloproteinase 2 Ameliorates Myocardial Remodeling in Mice With Chronic Pressure Overload Hypertension, April 1, 2006; 47(4): 711 - 717. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Janicki, G. L. Brower, J. D. Gardner, M. F. Forman, J. A. Stewart Jr., D. B. Murray, and A. L. Chancey Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload Cardiovasc Res, February 15, 2006; 69(3): 657 - 665. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Anne, R. Willems, T. Roskams, P. Sergeant, P. Herijgers, P. Holemans, H. Ector, and H. Heidbuchel Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation Cardiovasc Res, September 1, 2005; 67(4): 655 - 666. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Lindsey, D. K. Goshorn, C. E. Squires, G. P. Escobar, J. W. Hendrick, J. T. Mingoia, S. E. Sweterlitsch, and F. G. Spinale Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function Cardiovasc Res, May 1, 2005; 66(2): 410 - 419. [Abstract] [Full Text] [PDF] |
||||